Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG and Rituximab for GVHD Prevention in Non-Malignant Transplants
NCT01810926Phase 2Unknown
- Start
- Sep 2011
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, rituximab in graft-versus-host disease (GVHD). Status: unknown.
02
Drugs
antithymocyte globulin rabbitrituximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01810926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810926.